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BACKGROUND AND OBJECTIVES: The usefulness of the
Airway Questionnaire 20 (AQ20) – a short version of the St George’s
Respiratory Questionnaire (SGRQ) – to evaluate quality of life
(QOL) in asthmatic patients following a hospital admission was
assessed.
METHODS: At baseline and at six months following the index
admission, 135 asthmatic patients were asked to complete the AQ20
and the SGRQ. The patient’s peak flow, number of subsequent asthma
exacerbations and number of repeat hospital admissions were also
recorded.
RESULTS: The AQ20 scores ranged from 0 to 20, with a high score
indicating poor QOL. The AQ20 had good coverage, with no obvi-
ous ceiling or floor effects. In multiple regression analysis, all three
SGRQ components were important in predicting AQ20 scores
(R2 values were 61.9% and 73.1% for baseline and six-month scores,
respectively). The AQ20 was closely correlated with the SGRQ, but
not redundant when used together. Bias was low when the retest reli-
ability of the AQ20 was evaluated using the Bland-Altman method,
but variation was high (–0.64). Patients with subsequent exacerba-
tions (n=52) had higher AQ20 scores at six-month follow-up
(P=0.002). In logistic regression, the AQ20 score was closely associ-
ated with the incidence of exacerbations (OR 1.15, 95% CI 1.05 to
1.25), with a similar magnitude of association between the AQ20 and
the SGRQ. The AQ20 score did not correlate with peak flow at base-
line (r=–0.05; P=0.573) or at six months (r=–0.31; P=0.006), and
was not responsive to changes in peak flow (r=–0.06; P=0.583).
CONCLUSION: The AQ20 can be substituted for the more com-
plicated SGRQ in the assessment of QOL in patients following a hos-
pital admission for an asthma exacerbation.
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L’utilisation du questionnaire en 20 questions
sur les voies aériennes pour déceler les
changements à la qualité de vie des patients
asthmatiques et son association avec le 
questionnaire respiratoire du St. George Hospital
et ses paramètres cliniques
HISTORIQUE ET OBJECTIFS : Les auteurs ont analysé l’utilité du
questionnaire en 20 questions sur les voies aériennes (AQ20), une version
courte du questionnaire respiratoire du St. George Hospital (QRSG), pour
évaluer la qualité de vie (QDV) des patients asthmatiques après une
hospitalisation.
MÉTHODOLOGIE : Au moment de l’hospitalisation et six mois plus
tard, on a demandé à 135 patients asthmatiques de remplir l’AQ20 et le
QRSG. Chaque patient a également précisé son débit de pointe, le
nombre d’exacerbations subséquentes de l’asthme et le nombre de
réhospitalisations.
RÉSULTATS : Les indices de l’AQ20 variaient entre 0 et 20, un indice
élevé démontrant une mauvaise QDV. L’AQ20 offrait une bonne
couverture, sans effet de plafonnement ou effet plancher évident. Dans
l’analyse de régression multiple, les trois éléments du QRSG étaient
importants pour prévoir les indices de l’AQ20 (les valeurs R2 étaient de
61,9 % et de 73,1 % pour les indices de départ et au bout de six mois,
respectivement). L’AQ20 étaient étroitement relié au QRSG, mais pas
redondant lorsque les deux questionnaires étaient utilisés conjointement.
Le biais était faible lorsqu’on vérifiait la fiabilité de l’AQ20 par contretest
au moyen de la méthode de Bland-Altman, mais la variation était élevée
(–0,64). Les patients ayant des exacerbations subséquentes (n=52)
présentaient des indices d’AQ20 plus élevés au suivi de six mois
(P=0,002). Dans le cadre de la régression logistique, l’indice d’AQ20 était
étroitement relié à l’incidence des exacerbations (RR 1,15, 95 % IC 1,05
à 1,25), la magnitude d’association entre l’AQ20 et le QRSG étant
similaire. L’indice d’AQ20 n’était pas relié au débit de pointe de départ
(r=–0,05; P=0,573) ou au suivi de six mois (r=–0,31; P=0,006), et ne
réagissait pas aux variations du débit de pointe (r=–0,06; P=0,583).
CONCLUSION : On peut utiliser l’AQ20 pour remplacer le QRSG plus
complexe dans l’évaluation de la QDV des patients après une hospitalisa-
tion en raison d’une exacerbation de l’asthme. 
Health-related quality of life (HRQOL) has become animportant outcome in respiratory patients, as shown by
the development of several HRQOL questionnaires. Among
them is the St George’s Respiratory Questionnaire (SGRQ),
which is now one of the most widely used instruments for
assessing HRQOL in respiratory patients (1,2). However,
the use of this questionnaire is restricted mainly to research
settings because its interpretation is difficult and it takes a
significant amount of time to complete. The SGRQ consists
of two parts. Part one includes eight sets of questions, and
part two has six sections. Each section has four to 10 sets of
questions. The five-page questionnaire can take up to 20 min
to 30 min to complete and also needs a statistician to analyze
the results.
©2008 Pulsus Group Inc. All rights reserved
ORIGINAL ARTICLE
10349_win.qxd  11/04/2008  3:19 PM  Page 133
The Airway Questionnaire 20 (AQ20) was developed for
patients with asthma and chronic obstructive pulmonary dis-
ease (COPD) (3). It contains 20 items, with scores ranging
from 0 to 20 – high scores indicate poor QOL. It takes only a
few minutes to complete and has been validated in asthma (4)
and COPD (5) patients. However, it has been suggested that
the AQ20 may be less responsive than the SGRQ because it
measures fewer items. We postulated that the clinical parame-
ters used to assess asthma severity – such as peak flow, number
of asthma exacerbations and number of hospital admissions for
asthma – may be associated with a patient’s QOL. However,
there is limited data on the relationship between QOL and
these clinical parameters.
The aim of the present study was to evaluate the relation-
ship of the AQ20 to recurrent asthma exacerbations, inci-
dence of hospital readmissions and changes in peak flow, and
to assess the reliability and redundancy of the AQ20 compared
with the SGRQ in asthma patients after a hospital admission.
METHODS
All patients older than 16 years of age who were admitted to a
hospital with acute asthma between October 2000 and
October 2003 were eligible for the trial. Of 373 eligible
patients admitted with acute asthma, 154 were enrolled in the
study. A clinical diagnosis of asthma was made if the symptoms
of wheezing, breathlessness and cough met the criteria as per
the British Thoracic Society guidelines (6). Peak flow meas-
urements were also used to diagnose asthma. Patients subse-
quently found to have COPD were excluded at the first
follow-up appointment. A diagnosis of COPD was defined as a
patient with a forced expiratory volume in 1 s (FEV1) of less
than 80% of predicted and an FEV1/forced vital capacity of less
than 70% of predicted, with no significant improvement fol-
lowing a two-week course of steroids. Patients with pneumonia
and interstitial lung disease were excluded from the study.
Subjects underwent an initial assessment and then a follow-up
assessment after six months. Peak flow measurements, number
of recurrent exacerbations and number of hospital attendances
for emergency treatment were recorded. Patients were asked to
complete the AQ20 QOL questionnaire and the SGRQ during
their initial visit and at the six-month follow-up assessment.
QOL questionnaires
The AQ20 scores are out of a total of 20, with high scores indi-
cating a poor QOL. The SGRQ has three dimensions (symp-
toms, activity and impacts), and these can be summed to give
a total score (expressed as a percentage). High scores represent
a poor QOL.
Validity, redundancy and test-retest reliability of QOL
questionnaires
The AQ20 scores were assessed for coverage, as well as for ceil-
ing or floor effects, through descriptive statistics and inspec-
tion of histograms. The validity of the AQ20 was assessed by
its correlation with SGRQ scores. Multiple linear regression
was used to model AQ20 scores with the three components of
the SGRQ scores, and linear regression was used to model
AQ20 with the total SGRQ score. The aim was to test the
redundancy of the AQ20 when used in conjunction with the
SGRQ, by examining whether any of the components of the
SGRQ could explain the variations in the AQ20. If the two
questionnaires were redundant, then the variation seen in one
score could be entirely explained by one or more of the com-
ponents of the other score. In other words, when the SGRQ
components were used to predict AQ20 scores in multiple
regression, R2 was close to 100%. This would imply that the
AQ20 is not measuring any aspect of asthma severity over and
above that which is measured by the SGRQ, and is therefore
redundant.
A subset analysis of the patients who did not experience
any exacerbations was performed. These patients were assumed
to be clinically stable. This enabled an assessment of the test-
retest reliability of the questionnaire using Pearson’s correla-
tion coefficient and other methods for measuring agreement,
as proposed by Bland and Altman (7).
Relationship between QOL questionnaire and peak flow
The construct validity of the SGRQ and the AQ20 was
assessed by considering how well the questionnaire scores cor-
related with peak flow values, with predicted peak flow meas-
ured as a percentage of best peak flow. This analysis was
performed separately as a spot measurement in clinics at base-
line and after six months.
Relationship between QOL questionnaire and exacerbation
An exacerbation was defined as a drop in peak flow greater
than 30% of the best predicted or recorded value, requiring any
of the following: increased use of inhaled corticosteroids, use of
an emergency nebulized bronchodilator or a course of oral cor-
ticosteroids.
The study population was split into two groups. Patients
who experienced exacerbations during the six-month follow-up
period formed one group, and those who did not experience
any exacerbations formed the other group. A two-sample
t test was used to assess how well the AQ20 scores at six
months distinguished between these two groups. Logistic
regression was used to determine whether the QOL scores
were predictive of patients who experienced subsequent
exacerbations.
Relationship between QOL questionnaire and hospital
admission
The Mann-Whitney U (nonparametric) test was used to com-
pare six-month QOL scores with the incidence of repeat hos-
pital admissions within the six-month follow-up period.
RESULTS
The mean age of the patients was 40 years (range of 17 to
86 years of age). Mean predicted peak flow was 513 L/min. On
discharge from hospital, mean peak flow was 442 L/min, and at
six-month follow-up it was 424 L/min. Forty-seven per cent of
the subjects (n=72) in the present study population had no
asthma exacerbations during the six-month follow-up period,
compared with the other 52% of patients (n=80) who did
(information was not available for two subjects).
Validity of the questionnaires
The AQ20 scores covered approximately the whole range both
at baseline (mean [± SD] score 7.66±4.69), range 0 to 18) and
at six-month follow-up (mean score 8.00±5.03, range 0 to 19),
indicating good coverage. Both were approximately normally
distributed, with no clear evidence of a ceiling or floor effect
(Figure 1).
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Redundancy of the questionnaires
There was evidence of strong linear correlation between the
AQ20 and SGRQ scores, with higher AQ20 scores being asso-
ciated with higher SGRQ scores. Figure 2 shows the scatter
plot of AQ20 against total SGRQ score. Pearson’s correlation
coefficient between SGRQ and AQ20 was 0.72 (P<0.001) at
baseline and 0.85 (P<0.001) at six months. In univariate
analysis, the total SGRQ score was found to be important in
predicting AQ20 at both baseline and at six-month follow-up
assessment (R2=52.7% [P<0.001] and R2=72.3% [P<0.001],
respectively).
In multiple regression analysis, all three components of the
SGRQ were found to be important in predicting AQ20 scores
both at baseline (impact, P<0.001; activity, P<0.001; and
symptoms, P=0.020; R2=61.9%) and at six months (impact,
P<0.001; activity, P=0.005; and symptoms, P=0.064;
R2=73.1%).
Test-retest reliability of the questionnaires
The test-retest reliability of the AQ20 was assessed by compar-
ing baseline scores with six-month scores in the subgroup of
patients who did not experience any exacerbations (n=47).
These patients were assumed to be clinically stable during the
study period. The Pearson’s correlation coefficient between
baseline and six-month AQ20 scores was 0.72 (P<0.001). Bias
(or mean [± SD] difference) was –0.64±3.98, with 95% limits
of agreement of –8.44 to 7.17. Figure 3 shows the difference in
AQ20 score plotted against the mean AQ20 score for each
patient, along with the 95% limits of agreement (indicated by
dotted lines).
Relationship between QOL questionnaire and peak flow
There was no correlation between the AQ20 score and peak
flow at baseline (r=–0.05; P=0.573) or at six-month follow-up
(r=–0.31; P=0.006), shown in Table 1. There was also no evi-
dence that the AQ20 was responsive to changes in peak flow
between the two assessments (r=–0.06; P=0.583). Pearson’s
correlation between SGRQ scores and peak flow at baseline
was –0.064 (P=0.536); at six-month follow-up, –0.247
(P=0.031). There was no evidence that SGRQ was responsive
to changes in peak flow over the six-month period (r=–0.146;
P=0.211).
Relationship between QOL questionnaire and exacerbation
Forty-seven patients in the present study population had no
asthma exacerbations during the six-month follow-up period,
compared with the other 52 patients who did (information was
not available for two subjects). The mean AQ20 score at
six months was 6.32±5.26 in the group of patients with no
exacerbations and 9.48±4.38 (P=0.002) in the group that
experienced exacerbations. In univariate logistic regression,
both the AQ20 score (OR 1.15, 95% CI 1.05 to 1.25) and the
SGRQ score (OR 1.03, 95% CI 1.01 to 1.06) were significantly
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TABLE 1
Correlations* of the Airway Questionnaire 20 with peak
flow, symptoms, activity, impact and total St George’s
Respiratory Questionnaire (SGRQ) scores at baseline and
at six-month follow-up
Baseline Six-month Change
assessment assessment in scores
r P r P r P
Peak flow –0.05 0.573 –0.31 0.006 –0.06 0.583
Symptoms 0.56 <0.001 0.69 <0.001 0.47 <0.001
Activity 0.69 <0.001 0.72 <0.001 0.67 <0.001
Impact 0.72 <0.001 0.83 <0.001 0.55 <0.001














AQ20 score AQ20 score
Baseline Six months
Figure 1) Distribution of Airway Questionnaire 20 (AQ20) scores at
baseline and at six-month follow-up
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Figure 2) Pearson’s correlation coefficient between the St George’s
Respiratory Questionnaire (SGRQ) and the Airway Questionnaire 20






















Figure 3) Test-retest reliability of the Airway Questionnaire 20
(AQ20) with 95% limits of agreement (indicated by dotted lines).
Difference versus mean AQ20 (only patients with no exacerbations)
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associated with patients experiencing exacerbations during the
follow-up period.
Relationship between hospital admission and QOL
Seven patients were readmitted to hospital during the six-
month period. There was no significant difference between
median six-month AQ20 scores in the group who had not
been readmitted (median 8, interquartile range [IQR] 8) and
those who had (median 7, IQR 9; P=0.328). However, using
the SGRQ, the median six-month score for the group without
readmissions was 26 (IQR 37) compared with 47 (IQR 7) in
the group who had experienced a readmission (P=0.031).
DISCUSSION
There was a relatively low participation rate in the present
study because only 41% of eligible patients (154 of 373) were
recruited. This may be partly explained by several factors. For
example, researchers may not have had an opportunity to
recruit patients who were admitted over the weekend, late at
night or overnight, which are common periods of admission
in asthmatic patients. Most of our asthmatic patients were
young and had school or work commitments, making the
additional time and commitment to our clinics difficult. The
study was run to assess QOL after a hospital admission, rather
than to change management, which may have led to a lack of
motivation and interest for some patients to participate in
the study. A further 19 patients were unable to complete the
study because they did not attend the six-month follow-up
appointment. It is well recognized that poor compliance and
poor attendance at follow-up clinics are important factors in
patients with poorly controlled asthma. However, there did
not appear to be any selection bias. The 19 patients who were
unable to complete the study had a similar degree of asthma
severity as the rest of the group, and also had no more exac-
erbations or hospital admissions.
The AQ20 scores in our study population of asthmatic
patients showed good distribution, with no evidence of ceiling
or floor effects. This contradicted previous findings in which
AQ20 scores were skewed toward the mild end of the QOL
scale in COPD (3) and asthmatic (8) patients. The reason for
the difference in our findings may be partly explained by the
fact that we studied a more severe group of asthmatic patients.
Our patients were posthospital admission for an asthma exac-
erbation, whereas in the other study (8), patients were newly
diagnosed with asthma.
The present study demonstrated a close correlation
between AQ20 and SGRQ scores in asthmatic patients. This
finding has previously been reported in COPD patients (3).
Our data also suggested that the AQ20 had similar responsive-
ness to changes in the SGRQ scores, as previously reported by
Sanjuás et al (9). Similar trends were seen when the three
components of the SGRQ scores were considered separately.
This indicates that, while a high proportion of the variation
seen in AQ20 scores can be explained by these components,
some unexplained variation remains, and so the AQ20 is not
redundant when used in conjunction with the SGRQ.
However, the reverse is also true, ie, if we were to look at how
well the AQ20 predicts the SGRQ, we would find that the
SGRQ is not entirely redundant when used in conjunction
with the AQ20.
There was no evidence of correlation between the AQ20
score and peak flow as a proportion of best predicted value at
baseline assessment. Similarly, there was no evidence that
the AQ20 was responsive to changes in peak flow during the
follow-up period (P=0.583). However, at six-month follow-up,
higher AQ20 scores were associated with lower peak flow
values. This inconsistency may indicate that, while the two
variables are associated to some extent, other variables
besides peak flow – such as cough and the need to use
inhalers regularly – may also influence the way asthma affects
QOL. As with the AQ20, the SGRQ seems to have some
association with peak flow, but there are likely many other
variables, besides peak flow, that affect the way asthma influ-
ences patients’ QOL. A previous study (3) also concluded
that the AQ20 was only weakly associated with FEV1 in
COPD patients. In that study, multiple regression analysis
revealed that dyspnea and anxiety accounted for 43% of the
variance in the AQ20, whereas dyspnea and maximal oxygen
uptake accounted for 61% of the variance in the total score
of the SGRQ.
Our data found that the mean AQ20 score was significantly
higher by 3.16 (95% CI 1.24 to 5.09) in patients who had
experienced an exacerbation. Logistic regression showed that
both the AQ20 and the SGRQ scores were significantly asso-
ciated with the patients experiencing exacerbations, with
higher scores indicating that a subject was more likely to have
experienced exacerbations during the six-month period. The
AQ20 seems to be at least as useful as the SGRQ in this
respect.
Because only seven patients were readmitted to hospital
during the six-month period, the study had an insufficient
number of patients to assess the relative usefulness of the two
QOL questionnaires for identifing differences in QOL between
those patients readmitted and those not readmitted. This low
readmission rate may have been due to an early follow-up
offered to this patient group. There were no differences
between the groups as measured by the AQ20 (P=0.328). The
SGRQ did show some evidence of a different score between
the two groups, although the statistical power was low. A pre-
vious study (10) using a different questionnaire (risk screening
questionnaire) found a negative association between QOL and
number of hospital attendances. However, to our knowledge,
no study has previously looked at the effect of hospital readmis-
sion for asthma on QOL.
In recent years, the importance of HRQOL in the evalua-
tion of medical care and intervention practice has been widely
acknowledged. In particular, for chronic diseases like asthma or
COPD, the multidimensional concept of QOL has adopted the
role of an essential outcome parameter. Two types of instru-
ments can be used to categorize QOL: generic instruments,
which assess overall QOL, and disease-specific questionnaires,
which focus on specific aspects related to a particular disease. 
Over the past two decades, more than 1000 QOL instru-
ments have been developed, including nearly 20 disease-specific
inventories for patients with chronic lung diseases. In clinical
practice, both generic and specific questionnaires are used to
assess QOL in patients with asthma and COPD. Disease-specific
QOL instruments are considered to be more sensitive in estab-
lishing the specific restrictions related to asthma or COPD, and
in detecting possible improvements in QOL after treatment.
One study (11) compared two different QOL questionnaires
(the SGRQ and the ‘Fragebogen zur Lebensqualität bei
Asthma’) for their properties, limitations and special method-
ologies. They found that both questionnaires appeared to be
Win et al
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reliable, valid and efficient for the assessment of QOL in
patients with asthma or COPD, and may facilitate decision
making in the treatment process. Another study (5) also did a
comparative analysis between the AQ20/30 and the SGRQ in
patients with COPD and found that they were equally useful.
Several other QOL questionnaires – such as the Juniper Mini
Asthma Quality of Life Questionnaire, the Short Form 12 ques-
tionnaire and the Asthma Therapy Assessment Questionnaire –
were used to assess the relationships among QOL, severity and
control measures in asthma. Schatz et al (12) suggested that dis-
tinct components of patient-reported asthma health status may
be identified by factor analysis. Therefore, all of these studies are
in agreement with our findings that different QOL question-
naires have different components and usages.
CONCLUSION
Our data have provided evidence that the AQ20 QOL score
has good coverage, with no clear ceiling or floor effects. In
terms of reliability, it has low bias but high variation. The score
is highly correlated with the SGRQ score, although we have
found evidence to suggest that it is not redundant in this
respect. Both the AQ20 and the SGRQ scores were signifi-
cantly associated with the incidence of recurrent exacerbations
following the index asthma admission, with higher scores (and
therefore worse QOL) indicating that a subject is more likely
to experience exacerbations during the six-month period. We
found both scores to be equally useful in this respect.
Therefore, the AQ20 is a useful alternative to the SGRQ in
both academic and clinical practice.
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